問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Urology

更新時間:2023-09-19

陳威任
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

42Cases

2024-10-01 - 2029-09-30

Phase III

Active
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
  • Condition/Disease

    Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Test Drug

    Tablets Soft capsules Infusion solutions

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2035-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2021-01-04 - 2026-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2024-11-01 - 2031-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-12-30 - 2027-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-01-01 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-03-20 - 2030-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-26 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2020-06-01 - 2027-11-06

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5